Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMNDOTCMKTS:EMMANYSE:OGENNYSEAMERICAN:TOVX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMNDClearmind Medicine$1.03+1.0%$1.08$0.85▼$2.30$4.39M0.941.09 million shs34,097 shsEMMAEmmaus Life Sciences$0.02$0.02$0.00▼$0.11$1.05M6.1140,687 shs3,778 shsOGENOragenics$0.19-2.7%$0.23$0.16▼$3.43$4.12M0.871.67 million shs312,389 shsTOVXTheriva Biologics$1.41-0.8%$1.30$0.96▼$12.28$3.92M1.221.00 million shs12,352 shsFree Today: Your Guide to Smarter Options TradesLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMNDClearmind Medicine0.00%-8.93%-4.67%-26.09%-12.07%EMMAEmmaus Life Sciences0.00%+3.13%-12.70%+25.95%-83.50%OGENOragenics0.00%+12.57%-8.84%-36.04%-80.87%TOVXTheriva Biologics0.00%+4.85%+24.64%+6.04%-86.45%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCMNDClearmind Medicine1.1043 of 5 stars0.05.00.00.02.41.70.0EMMAEmmaus Life SciencesN/AN/AN/AN/AN/AN/AN/AN/AOGENOragenicsN/AN/AN/AN/AN/AN/AN/AN/ATOVXTheriva Biologics1.7227 of 5 stars3.53.00.00.01.10.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMNDClearmind Medicine 0.00N/AN/AN/AEMMAEmmaus Life Sciences 0.00N/AN/AN/AOGENOragenics 0.00N/AN/AN/ATOVXTheriva Biologics 3.00Buy$6.00325.53% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMNDClearmind MedicineN/AN/AN/AN/A$0.73 per shareN/AEMMAEmmaus Life Sciences$29.60M0.04N/AN/AN/A∞OGENOragenics$40K102.87N/AN/A$0.61 per share0.31TOVXTheriva BiologicsN/AN/AN/AN/A$54.22 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMNDClearmind Medicine-$5.26M-$1.22N/A∞N/AN/A-129.21%-61.15%6/12/2025 (Estimated)EMMAEmmaus Life Sciences-$3.73M-$0.14N/A∞N/A-17.11%N/A-12.66%N/AOGENOragenics-$20.66M-$1.70N/A∞N/AN/A-2,087.95%-486.56%N/ATOVXTheriva Biologics-$18.35M-$33.06N/A∞N/AN/A-76.12%-48.54%N/ALatest EMMA, OGEN, CMND, and TOVX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/14/2025Q4 2024EMMAEmmaus Life SciencesN/A-$0.03N/A-$0.03N/A$3.29 million3/13/2025Q1 2025CMNDClearmind MedicineN/A-$0.24N/A-$0.24N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCMNDClearmind MedicineN/AN/AN/AN/AN/AEMMAEmmaus Life SciencesN/AN/AN/AN/AN/AOGENOragenicsN/AN/AN/AN/AN/ATOVXTheriva BiologicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMNDClearmind Medicine0.011.721.72EMMAEmmaus Life SciencesN/A0.140.12OGENOragenicsN/A1.931.93TOVXTheriva BiologicsN/A2.672.67Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMNDClearmind Medicine96.05%EMMAEmmaus Life Sciences7.42%OGENOragenics18.71%TOVXTheriva Biologics6.17%Insider OwnershipCompanyInsider OwnershipCMNDClearmind MedicineN/AEMMAEmmaus Life Sciences35.00%OGENOragenics10.10%TOVXTheriva Biologics3.05%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMNDClearmind MedicineN/A4.27 millionN/ANot OptionableEMMAEmmaus Life Sciences6063.87 million41.51 millionNot OptionableOGENOragenics521.48 million10.98 millionN/ATOVXTheriva Biologics202.78 million2.70 millionNot OptionableEMMA, OGEN, CMND, and TOVX HeadlinesRecent News About These CompaniesTheriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant RecipientsApril 10, 2025 | globenewswire.comTheriva Biologics Completes Enrollment For VIRAGE Trial, Topline Data Expected In Q2 2025April 2, 2025 | nasdaq.comTheriva Biologics says IDMC considers VCN-01 to be well toleratedApril 2, 2025 | markets.businessinsider.comTheriva Biologics to Present at the CAGLA NeauxCancer 2025 Conference in New OrleansMarch 21, 2025 | nasdaq.comTheriva™ Biologics to Present at the 2025 NeauxCancer ConferenceMarch 19, 2025 | globenewswire.comAnalysts Offer Insights on Healthcare Companies: Myomo (MYO) and Theriva Biologics (TOVX)March 12, 2025 | markets.businessinsider.comTheriva Biologics Reports 2024 Financial Results and ProgressMarch 7, 2025 | tipranks.comTheriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial ResultsMarch 6, 2025 | globenewswire.comTheriva™ Biologics to Participate in the Q1 Investor Summit VirtualMarch 5, 2025 | markets.businessinsider.comTherivaâ„¢ Biologics to Participate in the Q1 Investor Summit VirtualMarch 5, 2025 | globenewswire.comTheriva Biologics Inc (TOVX) Surge: Analyzing Today’s Price IncreaseDecember 26, 2024 | bovnews.comTOVX’s Latest Twist: What’s Fueling the Unexpected Shifts in Theriva Biologics Inc’s Stock Price?December 25, 2024 | bovnews.comTheriva Biologics files to sell 7.69M shares of common stock, warrantsDecember 11, 2024 | markets.businessinsider.comTheriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic CancerDecember 5, 2024 | globenewswire.comTheriva Biologics Highlights Key Achievements in Q3 2024November 14, 2024 | tipranks.comTheriva™ Biologics Reports Third Quarter 2024 Operational Highlights and Financial ResultsNovember 13, 2024 | markets.businessinsider.comTheriva Biologics, Inc.: Theriva Biologics Reports Third Quarter 2024 Operational Highlights and Financial ResultsNovember 12, 2024 | finanznachrichten.de3 Penny Stocks to Watch Now, 11/5/24November 5, 2024 | msn.comTheriva Biologics Inc (TOVX) Stock Trading RecapNovember 5, 2024 | bovnews.comWill the Merck KGaA Grant Propel Theriva™ (TOVX) to New Heights?November 2, 2024 | bovnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonBy The Associated Press | April 6, 2025View Signs of a more buyer-friendly housing market emerge for the spring homebuying season5 Highest-Rated Dividend Stocks According to MarketBeatBy Thomas Hughes | April 10, 2025View 5 Highest-Rated Dividend Stocks According to MarketBeatCellectis Charts Course for 2025 With Boost From AstraZeneca DealBy Jeffrey Neal Johnson | April 22, 2025View Cellectis Charts Course for 2025 With Boost From AstraZeneca DealEMMA, OGEN, CMND, and TOVX Company DescriptionsClearmind Medicine NASDAQ:CMND$1.03 +0.01 (+0.98%) Closing price 03:59 PM EasternExtended Trading$1.04 +0.01 (+0.97%) As of 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; and with Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.Emmaus Life Sciences OTCMKTS:EMMA$0.02 0.00 (0.00%) As of 09:30 AM EasternEmmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. The company was founded in 2000 and is headquartered in Torrance, California.Oragenics NYSE:OGEN$0.19 -0.01 (-2.74%) Closing price 04:00 PM EasternExtended Trading$0.19 +0.00 (+1.25%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oragenics, Inc., a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus. The company's product candidates also comprise LPT3-04, a weight loss candidate; and SMaRT Replacement Therapy, a topical treatment to prevent dental carries. It has a license agreement with Noachis Terra Inc. for licensing of certain specified patent rights and biological materials relating to the use of pre-fusion coronavirus spike proteins; and a collaboration agreement ILH Holdings, Inc. for the development and commercialization of MU1140 and related homologs. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.Theriva Biologics NYSEAMERICAN:TOVX$1.41 -0.01 (-0.77%) Closing price 04:10 PM EasternExtended Trading$1.35 -0.06 (-4.26%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors. It also develops VCN-11 for treating solid tumors; SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage to prevent overgrowth and infection by pathogenic organisms, such Clostridioides difficile infection and vancomycin resistant Enterococci, and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. It has collaboration agreements with The University of Texas at Austin, Catalan Institute of Oncology, Fundació Privada Institut d'Investigacio Biomedica de Bellvitge, Saint Joan De Déu, and Massachusetts General Hospital, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Rebounds After Strong Earnings and Buyback Announcement Could Selling Taiwan Semiconductor Be Buffett’s Biggest Regret? The Bear Market Has Only Just Started - Here's Why MarketBeat Week in Review – 04/21 - 04/25 3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S. PepsiCo’s Stock Price is Disconnected From Reality: Time to Buy Bears Can Reap Big Benefits With These 3 Short ETF Bets Why Institutions Are Buying Super Micro Computer Stock Again Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
